The authors constructed an oncolytic measles virus engineered to express the tumor suppressor MG53 (TRIM72), designated rMeV-MG53, to evaluate whether MG53 arming could increase tumor cytotoxicity and antitumor immune activation in non-small cell lung cancer (NSCLC). According to the source, rMeV-MG53 retained replication kinetics comparable to the parental measles virus, indicating that transgene expression did not substantially impair viral replication under the reported experimental conditions.
In vitro, rMeV-MG53 produced significantly greater cytotoxicity in NSCLC cell lines compared with an unarmed control measles virus. The preprint reports that MG53 arming amplified tumor cell killing beyond levels achieved by the parental vector, establishing enhanced oncolytic potency attributed to the transgene.
Mechanistic experiments described in the source indicate that MG53 expression amplified caspase-3-dependent apoptosis and potentiated cleavage of Gasdermin E (GSDME). The combined observations support a model in which caspase-3 activation initiates apoptotic signaling that proceeds to GSDME cleavage, engaging GSDME-mediated pyroptosis as a key mechanism of rMeV-MG53-induced tumor cell death. Pharmacological inhibition data reported by the authors are interpreted to confirm that caspase-dependent apoptosis acts as the initiating event leading to pyroptosis in this context.
The authors evaluated alternative regulated cell-death pathways and report that necroptosis and ferroptosis did not significantly contribute to the cytotoxicity observed with rMeV-MG53. These negative findings were used to focus the mechanistic conclusion on apoptosis-to-pyroptosis conversion via caspase-3 and GSDME.
MG53 overexpression in tumor cells induced an intrinsic pro-inflammatory transcriptional signature. The signature was reported to be enriched for pathways including TNF signaling, NF-κB signaling, and IL-17 signaling. Compared with the unarmed measles virus control, rMeV-MG53 elicited stronger induction of type I interferon responses and pro-inflammatory cytokines, consistent with a more immunostimulatory tumor-cell phenotype following infection and transgene expression.
In a reported immunocompetent, measles virus–permissive syngeneic mouse model of NSCLC, intratumoral administration of rMeV-MG53 achieved superior tumor growth inhibition versus the unarmed virus. Tumors treated with rMeV-MG53 displayed amplified markers of caspase-3 activation and GSDME cleavage, supporting that the apoptosis-to-pyroptosis mechanism observed in vitro also occurred in vivo under the experimental conditions described.
The source reports selective upregulation of chemokines and cytokines, including Cxcl10, Ifng, and Il1b, following rMeV-MG53 treatment in vivo. This signature was accompanied by robust infiltration of cytotoxic immune effectors, specifically increased numbers of CD8+ T cells and Granzyme B+ effector cells in tumors. These changes indicate that rMeV-MG53 not only increases direct tumor cell killing but also remodels the tumor immune microenvironment toward a more inflammatory, effector-rich state.
The study documents compensatory upregulation of PD-L1 in the tumor microenvironment after rMeV-MG53 treatment. Based on this observation, the authors tested combination therapy of intratumoral rMeV-MG53 with systemic anti-PD-L1 blockade. The reported result is that the combination produced the strongest tumor suppression among the treatment groups evaluated, suggesting that virus-induced immune activation may be therapeutically augmented by checkpoint inhibition.
The preprint concludes that arming an oncolytic measles virus with MG53 couples enhanced tumor cytotoxicity driven by caspase-3/GSDME-mediated pyroptosis with broad immune microenvironment remodeling, including type I interferon and pro-inflammatory cytokine induction and recruitment of CD8+ effector cells. These dual effects reportedly sensitize immune-resistant NSCLC to checkpoint blockade, as shown by improved outcomes when rMeV-MG53 was combined with anti-PD-L1 therapy in the reported syngeneic model.
Limitations noted in the source: this work is presented as a preprint and has not been peer reviewed. Details such as specific experimental conditions, sample sizes, quantitative effect sizes, safety assessments, and long-term outcomes were not provided in the summary abstract and therefore are not reported here. Funders and a competing interest statement were listed by the authors in the source.